UroGen Pharma Doses First Patient In Phase 3 Trial Of UGN-103 For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer, Featuring Improved Manufacturing And Reconstitution Process
UroGen Pharma Doses First Patient In Phase 3 Trial Of UGN-103 For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer, Featuring Improved Manufacturing And Reconstitution Process
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.